Technical Analysis for HRMY - Harmony Biosciences Holdings, Inc.

Grade Last Price % Change Price Change
F 29.24 0.72% 0.21
HRMY closed down 0.96 percent on Friday, May 17, 2024, on 76 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 29
*** please verify all earnings dates ***
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.72%
Down 4 Days in a Row Weakness 0.72%
Oversold Stochastic Weakness 0.72%
Stochastic Reached Oversold Weakness -0.24%
Down 3 Days in a Row Weakness -0.24%
Oversold Stochastic Weakness -0.24%
20 DMA Resistance Bearish -1.55%
MACD Bearish Signal Line Cross Bearish -1.55%
Multiple of Ten Bearish Other -1.55%
Inside Day Range Contraction -1.55%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 1 hour ago
Rose Above Previous Day's High about 2 hours ago
Up 1% about 2 hours ago
Fell Below Previous Day's Low 3 days ago
Down 1% 3 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants

Is HRMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.265
52 Week Low 18.6112
Average Volume 438,923
200-Day Moving Average 30.98
50-Day Moving Average 30.83
20-Day Moving Average 30.14
10-Day Moving Average 30.35
Average True Range 1.25
RSI (14) 40.48
ADX 16.73
+DI 20.65
-DI 22.04
Chandelier Exit (Long, 3 ATRs) 30.65
Chandelier Exit (Short, 3 ATRs) 31.89
Upper Bollinger Bands 32.10
Lower Bollinger Band 28.19
Percent B (%b) 0.22
BandWidth 12.97
MACD Line -0.26
MACD Signal Line -0.14
MACD Histogram -0.1279
Fundamentals Value
Market Cap 1.7 Billion
Num Shares 58.6 Million
EPS 2.47
Price-to-Earnings (P/E) Ratio 11.75
Price-to-Sales 3.82
Price-to-Book 4.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.06
Resistance 3 (R3) 30.13 29.84 29.89
Resistance 2 (R2) 29.84 29.58 29.81 29.83
Resistance 1 (R1) 29.44 29.42 29.30 29.37 29.78
Pivot Point 29.15 29.15 29.08 29.12 29.15
Support 1 (S1) 28.75 28.89 28.61 28.69 28.28
Support 2 (S2) 28.46 28.73 28.43 28.23
Support 3 (S3) 28.06 28.46 28.17
Support 4 (S4) 28.00